When the CNS is injured, damaged axons do not regenerate. This failure is due in part to the growth-inhibitory environment that forms at the injury site. Myelin-associated molecules, repulsive axon guidance molecules, and extracellular matrix molecules including chondroitin sulfate proteoglycans (CSPGs) found within the glial scar inhibit axon regeneration but the intracellular signaling mechanisms triggered by these diverse molecules remain largely unknown. Here we provide biochemical and functional evidence that atypical protein kinase C (PKC) and polarity (Par) complex proteins mediate axon growth inhibition. Treatment of postnatal rat neurons in vitro with the NG2 CSPG, a major component of the glial scar, activates PKC, and this activation is both necessary and sufficient to inhibit axonal growth. NG2 treatment also activates Cdc42, increases the association of Par6 with PKC, and leads to a Par3-dependent activation of Rac1. Transfection of neurons with kinase-dead forms of PKC, dominant-negative forms of Cdc42, or mutant forms of Par6 that do not bind to Cdc42 prevent NG2-induced growth inhibition. Similarly, transfection with either a phosphomutant Par3 (S824A) or dominantnegative Rac1 prevent inhibition, whereas expression of constitutively active Rac1 inhibits axon growth on control surfaces. These results suggest a model in which NG2 binding to neurons activates PKC and modifies Par complex function. They also identify the Par complex as a novel therapeutic target for promoting axon regeneration after CNS injury.
Introduction
The growth and guidance of axonal processes during nervous system development is regulated by extracellular cues that attract or repel axonal growth cones (Tessier-Lavigne and Goodman, 1996) . After binding to their receptors, these cues activate intracellular second messenger systems that alter the functions of the actin and microtubule-based cytoskeletal motors that control growth cone motility and drive axon extension (Bashaw and Klein, 2010) . Many repulsive axon guidance molecules are reexpressed at high levels at CNS injury sites (Yiu and He, 2006) . Together with myelin-associated inhibitory molecules and chondroitin sulfate proteoglycans (CSPGs), they create a biochemical barrier to successful axon regeneration. Understanding the mechanisms by which these diverse molecules cause axon growth inhibition may lead to new treatments to promote regeneration after injury.
Severed adult axons must reform a growth cone to regenerate. Peripheral neurons do this successfully, but CNS neurons form dystrophic end bulbs that remain embedded in the glial scar at the injury site (Ramó n y Cajal, 1928) . Growth cone formation requires the reestablishment of the actin and microtubule based cytoskeletal motors (Bradke et al., 2012) . During development, growth cone formation and axonogenesis is regulated by the polarity (Par) complex (Arimura and Kaibuchi, 2007) . This complex of atypical PKC, Par6, and Par3 is activated by Cdc42, and in turn regulates the location and activity of Rac1. Axonogenesis requires the transport and accumulation of Par3 and Par6 at the tip of the neurite that will become the axon (Shi et al., 2003; Schwamborn and Puschel, 2004; Nishimura et al., 2005) and also requires the activity of PKC (Chen et al., 2006) . By regulating the organization and coordinating the functions of actin microfilaments and microtubules, the Par complex is necessary for axon specification, growth cone formation, and axon extension.
Here we asked whether the inhibition of axon growth induced by injury-associated molecules involves an alteration of PKC and Par complex function. We focused on the NG2 CSPG because it is a major proteoglycan constituent of glial scars (Jones et al., 2002; Tang et al., 2003) . NG2 is secreted or shed predominantly from reactive oligodendrocyte precursor cells and reaches maximum levels at injury sites within 5-7 d after injury. NG2 inhibits axon growth in vitro, forms barriers to axon extension, and induces growth cone collapse (Dou and Fidler et al., 1999; Chen et al., 2002; Ughrin et al., 2003) , although these findings remain controversial (Yang et al., 2006a; Busch et al., 2010) . After spinal cord injury, the dystrophic ends of damaged axons are embedded in NG2-rich regions of the glial scar (Jones et al., 2002) , and the infusion of function-blocking antibodies against NG2 allows sensory axons to grow into and out of an injury site (Tan et al., 2006) . Thus, treating neurons in vitro with NG2 provides a model system for determining the intracellular mechanisms of axon growth inhibition. Here, we show that the inhibition of axon growth induced by NG2 requires the activation of Cdc42 and PKC. This activation results in an alteration in Par complex function. These studies define a novel function for Par3 in axon repulsion and identify a new therapeutic target for encouraging axon regeneration after CNS injury.
Materials and Methods

Antibodies
Anti-PKC antibody (sc-216), anti-Rac1 antibody (sc-217), and antiMyc antibody (sc-40) were purchased from Santa Cruz Biotechnology. Anti-Phospho-PKC/ (9378) antibody was purchased from Cell Signaling Technology. Anti-Par3 antibody (07-330) and anti-Tau (MAB361) was purchased from Millipore. Monoclonal anti-FLAGM2 antibody (F3165) and anti-␤-actin antibody (A5316) were purchased from Sigma. Living Colors DsRed polyclonal antibody (632496) was purchased from Clontech. Neuronal Class III ␤-tubulin (Tuj1) monoclonal antibody was purchased from Covance.
siRNAs
To target endogenous PKC, ON-TARGETplus SMARTpool PRCKZ, a mixture of the following different sequences of siRNA targeting rat PKC (NM 022507), was purchased from Dharmacon: 5Ј-CCACGACGAUGA GGAUAUC-3Ј (864 -882), 5Ј-UCGGAAACAUGACAAUAUC-3Ј (654 -672), 5Ј-UCACACGUCUUGAAAGGAU-3Ј (1456 -1474), and 5Ј-CGAUGCCGAUGGACACAUU-3Ј (1152-1170).
Scrambled control siRNA was kindly provided by H. Colognato (Stony Brook University, Stony Brook, NY).
Plasmids pCAG-EGFP.
This CMV early enhancer/chicken ␤ actin promoter (CAG)-based plasmid was constructed to overexpress exogenous proteins in primary cells. pCIG2 (a gift from Y. Zou, University of California at San Diego, San Diego, CA) was linearized with MscI, and the resulting 5Ј overhang sequences were Klenow-filled. The cassette containing multiple cloning site (MCS), IRES, and EGFP sequences was removed by XhoI digestion. A fragment containing the MCS and EGFP ORF was obtained from pEGFP-N1 (Clontech) by XhoI and NotI digestion and ligated into the linearized pCIG2.
pCAG-PKC-EGFP. The ORF of rat PKC was amplified by PCR from pHACE-PKC (a kind gift from J. So, Inha University, Incheon, South Korea) with the primers 5Ј-CCGCTCGAGCT GCCACCATGCCCAGC AGGACCGACCCC-3Ј and 5Ј-CGGAATTCTGCACGGA CTCCTCAGC AGACAG-3Ј and cloned into the XhoI and EcoRI sites of pCAG-EGFP.
pCAGJC. For pCAGJC, the expression cassette of EGFP in pCAG-EGFP was excised by AgeI and BsrGI digestion. The resulting overhang sequences were filled in with Klenow and self-ligated. This vector was used to clone small epitope-tagged expression cassettes.
pCAGJC-FLAG-PKC. The FLAG-tagged mouse PKC expression cassette was excised with EcoRI from pCIG2-PKC WT (a kind gift from Y. Zou) and subcloned into the same sites of pCAGJC.
pCAGJC-FLAG-PKC T410E. To mutate the phosphorylation site of PKC, an in vitro site-directed mutagenesis kit (Quick Change) from Agilent Technologies was used. pCAGJC-FLAG-PKC was PCRamplified with the primers 5Ј-GGCCCCGGTGATACAACAAGCGAG TTTTGTGGAACCCCGAACTAT-3Ј and 5Ј-ATAGTTCGGGGTTCCA CAAAACTCGCTTGTTGTATCACCGGGGCC-3. The mutation was confirmed by sequencing analysis.
pCAGJC-FLAG-PKC T410/560E. pCAGJC-FLAG-PKC T410E was PCR-amplified with the primers 5Ј-GCGAGCCTGTGCAGCTGGAACC AGATGATGAGGACGTC-3Ј and 5Ј-GACGTCCTCATCATCTGGTTC CAGCTGCACAGGCTCGC-3Ј. The mutation was confirmed by sequencing analysis.
pCIG2-FLAG-PKC K281W (kinase deficiency). pCIG2-FLAG-PKC K281W was a kind gift from Y. Zou (Wolf et al., 2008) .
pCAGJC-myc-Par6C. For pCAGJC-myc-Par6C, the Myc-tagged human Par6C expression cassette was PCR-amplified from pk-myc-Par6C (Joberty et al., 2000) (Addgene plasmid 15474) with the primers 5Ј-GC GAGCTCCTGCCACCATGGCCCGGCCGCAGAGGACT-3Јand5Ј-CG GAATTCTCAGAGGCTGAAGCCACTACCATC-3Ј and cloned into the SacI and EcoRI sites of pCAGJC.
pCAGJC-mycPar6⌬CRIB. The semi-CRIB domain sequence of Myctagged Par6C was deleted by using PCR as follows. First, the 5Ј fragment of semi-CRIB domain was PCR-amplified with the primers 5Ј-GCGAGC TCCTGCCACCATGGCCCGGCCGCAGAGGACT-3Ј and 5Ј-CCGTCG GTGGGTCTCAGGCAGTGCCACTGGCCGCAGCAAGAG-3Ј, and the 3Ј fragment with primers 5Ј-CTCTTGCTGCGGCCAGTGGCACTGCC TGAGACCCACCGACGG-3Ј and 5Ј-CGGAATTCTCAGAGGCTGAA GCCACTACCATC-3Ј. These two fragments were then adjoined by PCR with the primers GCGAGCTCCTGCCACCATGGCCCGGCCGCAGA GGACT-3Ј and 5Ј-CGGAATTCTCAGAGGCTGAAGCCACTACCA TC-3Ј and cloned into the SacI and EcoRI sites of pCAGJC.
pCAGJC-mycPar6⌬135P. For pCAGJC-mycPar6⌬135P, the proline residue at position 135 of Myc-tagged Par6C expression cassette was deleted using PCR. First, the 5Ј fragment of semi-CRIB domain was PCR-amplified with the primers 5Ј-GCGAGCTCCTGCCACCATGGCCCGGCCGCAGA GGACT-3Ј and 5Ј-GGAAACCTGGCGGAAATCTTGCAGGCTGATTAG CAAGGGTGG-3Ј, and 3Ј fragment with primers 5Ј-CCACCCTTGCTAAT CAGCCTGCAAGATTTCCGCCAGGTTTCC-3Ј and 5Ј-CGGAATTCTC AGAGGCTGAAGCCACTACCATC-3Ј. These two fragments are adjoined by PCR with the primers 5Ј-GCGAGCTCCTGCCACCATGGCCCGGCCG CAGAGGACT-3Ј and 5Ј-CGGAATTCTCAGAGGCTGAAGCCACTAC CATC-3Ј and cloned into the SacI and EcoRI sites of pCAGJC.
pCAGJC-myc-Par3b. For pCAGJC-myc-Par3b, the expression cassette of Myc-tagged Par3b was cut from pk-myc-Par3b (Joberty et al., 2000) (Addgene plasmid 19388) with HindIII and EcoRI and cloned into the same sites of pCAGJC.
pCAGJC-myc-Par3b S824A. To mutate the PKC phosphorylation site of Par3b, pCAGJC-myc-Par3b was PCR-amplified with the primers 5Ј-GAAG GATTTGGACGTCAGGCTATGTCAGAAAAACGCACA-3Јand5Ј-TGTG CGTTTTTCTGACATAGCCTGACGTCCAAATCCTTC-3Ј. The PCR mixture was treated with DpnI to remove the template strands and used for transformation. The mutation of each plasmid was confirmed by sequencing analysis.
pCAGJC-dTomato. pC1-dTomato (a kind gift form N. Kumamoto, Osaka University, Osaka, Japan) containing a dTomato version of pC1-EGFP (Clontech) was digested by NheI, and the resulting sticky ends were blunted by Klenow. The fragment including the dTomato expression cassette and MCS sequence excised with XmaI and was cloned into the XhoI (Klenow-filled) and XmaI sites of pCAGJC.
pCAGJC . For pCAGJC-dTom-Cdc42 WT and pCAGJC-dTom-Cdc42 DN(T17N), the Cdc42 expression cassettes of wild-type (WT) and dominant-negative (DN) pcDNA3-EGFP-Cdc42, respectively, were excised by BsrGI and XhoI and then cloned into the same sites of pCAGJC-dTomato.
pCAGJC-dTom-Cdc42CA(Q61L). To mutate the wild type of Cdc42 into the constitutively active (CA) form, pCAGJC-dTom-Cdc42 WT was PCR-amplified with the primers 5Ј-TTTTTGATACTGCAGGGCTAGA GGATTATGACAGATT-3Ј and 5Ј-AATCTGTCATAATCCTCTAGCC CTGCAGTATCAAAAA-3Ј. The mutation of each plasmid was confirmed by sequencing analysis.
pCAGJC-dTom-Rac1 WT, . Expression cassettes of wild-type, dominant-negative, and constitutively active Rac1 were amplified from pCMV-HA-Rac1 (a gift from S. Halegoua, Stony Brook University, Stony Brook, NY) by PCR with the primers 5Ј-CCGCTCGAGCTATGCAGGCCATCA AGTGTGTGG-3Ј and 5Ј-CGGAATTCTTACAACAGCAGGCATTTTC TC-3Ј and cloned into the XhoI and EcoRI sites of pCAGJC-dTomato.
Purification of NG2. A recombinant fragment corresponding to the entire extracellular domain (ECD) of NG2 was purified as described previously (Tillet et al., 1997; Ughrin et al., 2003) . ley hippocampi were purchased from BrainBits and dissociated following the manufacturer's protocol. Neurons were plated onto glass coverslips coated with poly-L-lysine or poly-L-lysine plus NG2 CSPG at a density of 5-10 ϫ 10 3 cells/cm 2 and cultured at 37°C and 5% CO 2 for 24 -48 h.
Adult mouse dorsal root ganglia culture and neurite measurement
Dorsal root ganglia (DRGs) were dissected from 6-week-old mice and treated with dispase II (Roche) and collagenase (Sigma) and titurated. Approximately 1000 cells were plated onto a 15 mm glass coverslip coated with either 50 g/ml PLL and 2 g/ml laminin alone (control substrate) or PLL and 2 g/ml laminin along with 10 g/ml NG2 ECD (NG2 substrate). Cells were cultured in Neurobasal-A supplemented with B27 (Invitrogen) for 48 h, fixed with 4% paraformaldehyde in 100 mM phosphate buffer, and stained with anti-Tuj1 antibody (1:1000). Cells were visualized using Alexa Fluor 488-or Alexa Fluor 594-conjugated donkey anti-rabbit secondary antibodies (1:1000). To quantify the average neurite length per cell, 5 to 10 fields per coverslip were randomly selected and imaged with fluorescence microscopy (Axio Imager system, Carl Zeiss) for each group. The images of DRGs were binarized and skeletonized with MetaMorph software. The total white pixel numbers of each cell were counted and logged onto an Excel spreadsheet, and the mean number of pixels per cell was calculated.
Immunocytochemistry
Cultures were fixed and stained as described previously (Dewald et al., 2011) . Primary antibodies were polyclonal anti-PKC (1:200; Santa Cruz Biotechnology), anti-Par3 (1:100; Millipore), monoclonal anti-Tau (1: 100; Millipore), Neuronal Class III ␤-tubulin (Tuj1) monoclonal antibody (1:500; Covance), and anti-GAP43 (1:5000; gift from D. Schreyer, University of Saskatoon, Saskatoon, SK, Canada). Alexa Flour 488-or 594-conjugated donkey anti-mouse or donkey anti-rabbit secondary antibodies (diluted 1:1000, 30 min incubation; Invitrogen) were used to detect the primary antibodies. For the quantitation of PKC and Par3 immunoreactivity, between 1 and 15 Z-stack images per cell were acquired with an Olympus FluoView 1000 confocal laser-scanning microscope. FluoView 1000 viewer and MetaMorph software were used for the analysis of each image. For PKC, a plane containing a middle part of the cell body was selected and exported for analysis to the MetaMorph software. Pixel intensity distribution was measured across the selected cell body image with the linescan function of MetaMorph software. For Par3, in each acquired cell image, a plane containing the brightest Par3 signal in the axonal compartment was selected, a line was traced along the axon, and its average pixel intensity was measured with the linescan function of MetaMorph. To measure the Par3 signal in the cell body, a circle was traced along the edge of each cell, and the average pixel intensity of the area was measured with the area measurement tool of MetaMorph software. To calculate the Par3 signal ratio between the soma and axon of each cell, the mean pixel intensity of Par3 of the cell body was divided by that the of axon.
Microscopy
Cells were fixed with 4% paraformaldehyde. After washing and staining, cells were mounted in fluorescence mounting medium (Southern Biotech) and stored at 4°C. Cells were imaged by epifluorescence on a Axioplan 2 imaging microscope (Carl Zeiss) with a 20ϫ numerical aperture (NA) 0.75 plan-Apochromat objective. Digital (16 bit) images were acquired with a cooled charge-coupled device (Axiocam; Carl Zeiss) using AxioVision 4.7.2 software.
For confocal laser scanning microscopy, cells were imaged on an FV 1000 confocal microscope (Olympus) equipped with either a 40ϫ (UPlan FL N, 1.30 NA) or 60ϫ (PLAN APO, 1.42 NA) oil-immersion objective. Digital (12 bit) images were acquired with a cooled chargecoupled device using FV10-ASW 2.1 software and processed using MetaMorph software (Molecular Devices).
Neurite outgrowth assay
Neurite outgrowth assay were performed as described previously (Dou and . Briefly, CGNs were plated at the density of 1 ϫ 10 4 cells onto a 15 mm glass coverslip treated either with 50 g/ml PLL and 2 g/ml laminin alone (control substrate) or PLL and 2 g/ml laminin along with one of the following: NG2 ECD (10 g/ml) (Ughrin et al., 2003) , neurocan (10 g/ml) (Asher at al., 2000), aggrecan (10 g/ml; Sigma), chick brain CSPGs (5 g/ml; Millipore), or myelin membranes [20 -40 g/ml total protein; prepared according to the procedure of Norton and Poduslo (1973) ]. After electroporation, cells were plated, cultured in DMEM containing 10% FBS for 20 -24 h, and fixed with 4% paraformaldehyde in 100 mM phosphate buffer. In some cases, the cells were stained with a neuron-specific marker such as ␤-tubulin III, Tuj1, or anti-GAP43 antibody. In other cases, cells were imaged using the dTomato fluorescence. To quantify neurite lengths, 5 to 10 fields per coverslip were randomly selected and imaged. A neurite was defined as a process extending from the neuronal cell body by more than a cell diameter. Length was measured from the axon initial segment to the tip of neurite using the line measurement tool in MetaMorph (Molecular Devices). For cells that had more than one neurite, only the longest one was measured. In the genetic modification experiments, only transfected cells marked by dTomato expression were counted for analysis. Each experiment was repeated at least three times unless noted otherwise, and comprised duplicate coverslips for each condition. A minimum of 300 cells were measured for each experimental condition.
Transient transfections
The Amaxa Nucleofection system (Lonza) was used to deliver exogenous genes or siRNA into primary neurons. For each nucleofection, 5 ϫ 10 6 of dissociated CGNs and either 0.75-2.5 g of plasmid DNA or 10 -200 pmole of siRNA was suspended in 100 l of nucleofection solution and nucleofected with program G-013. The cell suspensions were immediately diluted with 1 ml of DMEM containing 10% FBS, and 50 -100 l of cell suspension was plated onto coated coverslips. For biochemical analysis 2-3 ϫ 10 7 cells were plated onto PLL-coated 60 mm culture dishes. HT22 cells, an immortalized mouse hippocampal cell line (Behl et al., 1995) , were transfected with 4 g of plasmid DNA using Lipofectamine 2000 (Invitrogen) according to the manufacturer's instructions.
NG2 treatment, immunoblot, and immunoprecipitation
For biochemical analysis, either 5 ϫ 10 6 nontransfected CGNs or 1 ϫ 10 7 transfected CGNs were plated onto each 35 mm culture dish coated with 25 g/ml PLL and cultured in Neurobasal-A with B27 supplement overnight. HT22 cells were plated 3 ϫ 10 5 onto 35 mm culture dishes and cultured in DMEM containing 10% FBS overnight. Primary cells were starved in Neurobasal-A without B27 for 3-5 h in the presence or absence of relevant compounds. HT22 cells were starved either in serum-free DMEM for 3-5 h or in Neurobasal-A with B27 overnight followed by Neurobasal-A without B27 for 3-5 h before treatment.
After treatment, the cells were washed twice with cold PBS and lysed in either 0.3% or 1.0% CHAPS lysis buffer (20 mM phosphate buffer, pH 7.4, 150 mM NaCl, 1 mM EDTA, and either 0.3% or 1.0% CHAPS) supplemented with proteinase and phosphatase inhibitor cocktail (Roche). Insoluble fractions were removed by centrifugation at 16,000 ϫ g for 10 min, and soluble fractions were subjected to immunoblotting or immunoprecipitation.
For immunoprecipitation, 1-2 g of primary antibody and 20 l of protein G beads (Roche) were added to 100 -500 g of cell lysate and incubated under constant agitation for 2-4 h or overnight at 4°C. The resulting bead-bound immune complexes were washed four times with the lysis buffer, resuspended, and boiled in 25-50 l of 2ϫ protein sample buffer. The primary antibodies and their dilution ratio were as follows: anti-PKC antibody (1:1000), anti-Rac1 antibody (1:1000), antiMyc antibody (1:1000), anti-phospho-PKC/ antibody (1:1000), anti-Par3 antibody (1:2000), monoclonal anti-FLAG/M2 antibody (1:2000), anti-␤-actin antibody (1:50000), and Living Colors DsRed polyclonal antibody (1: 2000). The blots were washed and incubated in horseradish peroxidaseconjugated secondary antibodies (1:2000; GE Healthcare) for 30 min to 2 h. Then, the blots were washed, developed with the GE Healthcare ECL kit, and exposed to HyblotCL autoradiograph film (Denville Scientific) to detect specific chemoluminescence.
For the preparation of cytoplasmic and membrane fractions of cells, CGNs were grown overnight on coated tissue cultures dishes, and the monolayers were lysed in 0.02 M Tris-Cl, pH 7.4, 0.25 M sucrose, 10 mM EGTA, 2 mM EDTA, 10 g/ml aprotinin and leupeptin, and 0.2 mM PMSF and centrifuged at 130,000 ϫ g for 30 min. The resulting pellet was resuspended in the same solution containing 1% Triton X-100, kept on ice for 60 min, and centrifuged again. Protein was determined with the Bradford reagent (Bio-Rad). In some experiments, 2 M ZIP peptide (cell-permeable pseudosubstrate peptide inhibitor, N-Myr-SIYRRGARRWRKL-OH, Enzo Life Sciences) was added 3 h before lysis, or cells were treated with phorbal-12-myrisate-13-acetate (PMA; 200 nM) for 5 min before lysis.
Cdc42 activation assay and in vitro GDP and GTP loading. HT22 cells were transfected with dTomato-tagged Cdc42 (dTom-Cdc42) and Myc-tagged Par6 (Myc-Par6). For in vitro loading, EDTA was added to cell lysates to 20 mM final concentration. The lysates were then incubated with either 1 mM GDP or 100 M GTP␥S with constant agitation at 30°C for 30 min. The reactions were stopped by adding MgCl 2 (to 60 mM, final concentration) and used for the subsequent immunoprecipitation procedure.
In vitro kinase assay. The activity of PKC was assayed by measuring the rate of phosphorylation of the PKC-specific peptide substrate (Kazanietz et al., 1993; Nishikawa et al., 1997) . Recombinant plasmid of FLAG PKC (pCIG2-FLAG PKC) was transfected into CGNs and expressed overnight. Cells were serum-starved for 3-5 h and treated with 10 g/ml NG2 for 10 -30 min. After treatment, cells were immediately washed with cold PBS and lysed in 0.3% CHAPS lysis buffer (20 mM phosphate buffer, pH7.4, 150 mM NaCl, 1 mM EDTA, and 0.3% CHAPS) supplemented with proteinase and phosphatase inhibitor cocktail (Roche). The insoluble fraction was removed by centrifugation at 16,000 ϫ g for 10 min. One hundred micrograms of lysate were immunoprecipitated with 1 g of anti-FLAG antibody and 20 l of protein G bead for 2 h under constant agitation. The beads and immune complexes were centrifuged and washed in 0.3% CHAPS lysis buffer. After three washes, the beads were washed once with and then resuspended in 40 l of kinase buffer (8 mM MOPS, pH 7.0, 1 mM EDTA), and 2-8 l of resuspension was diluted in the reaction mixture containing 50 M peptide substrate and 20 g/ml phosphatidylserine. The assay mixtures were preincubated at 30°C for 10 min. The reaction was started by adding 5 Ci of ␥ 32 P]ATP. After 20 min, 20 l of assay mixture was spotted onto P81 paper (Millipore Biotechnology) to stop the reaction. The paper was washed three times with 0.75% phosphoric acid for 5 min and once with acetone for 5 min, air dried, and transferred into a scintillation vial. Ten milliliters of scintillation mixture was added to the each vial, and radiation activity was measured in a Beckman LS6500 scintillating counter.
Stripe assay. The stripe assay (Vielmetter et al., 1990 ) was performed as follows. NG2 (20 g/ml) or Fc in sterile PBS containing a coloring antibody (goat anti-human-FC-Cy3; Invitrogen) was applied to 100 m channels of a polydimethylsiloxane (Dow Corning) matrix for 2 h at 37°C on a PLL-coated coverslip. Clustered Ephrin-A5 (10 g/ml) was printed directly on glass surfaces. After removing the matrix and rinsing with PBS, the patterns were additionally coated with 20 g/ml laminin for 1 h at 37°C. Retinal strip explants (E7) of 300 m width were cultivated for 24 h on the patterned coverslips. Afterward, 5 M Myr-PKCpseudosubstrate peptide (ZIP peptide; Invitrogen), inactivated ZIP peptide (proteinase K treatment at 37 o for 30 min followed by heat inactivation at 99 o for 15 min), or heat-inactivated proteinase K (99 o ,15 min) in methylcellulose containing F-12 medium was added for another 12 h. Explant cultures were fixed and stained for laminin and actin.
Explant axons covering at least a 1 ϫ 0.8 mm of the patterned surface were analyzed. Image quantification was done with the ImageJ JaCop plug-in for colocalization. The actin signal overlapping the laminin signal was calculated using Manders' coefficient. Data were expressed as the percentage of neurons avoiding the protein of interest.
Analysis of neuronal polarity
To quantify the polarization of cells, axons and dendrites were determined by immunostaining; a tau-positive process extending more than twice a cell diameter was defined as an axon. Phalloidin-positive, Taunegative processes were defined as dendrites. More than 130 cells for each group were examined from three independent experiments.
Statistics
Statistical analysis was performed using SigmaStat software (Systat Software), and either Students' t test or Mann-Whitney rank sum test was used. For comparison of multiple data sets with normal distribution, one-way ANOVA was used followed by post hoc Tukey's test. For data sets that failed to pass normality test, ANOVA on ranks was used followed by Dunn's post test. Data are presented as mean Ϯ SE, and a value of p Ͻ 0.05 is considered significant.
Results
To assess the role of PKC and the Par complex in axon growth inhibition, we grew postnatal rat CGNs on surfaces coated with either NG2, aggrecan, neurocan, chick brain CSPGs, or rat brain myelin, and treated the cultures with isoform-specific inhibitors of PKC. As shown in Figure 1A and consistent with previous studies (Hasegawa et al., 2004; Sivasankaran et al., 2004) Gö6976 [12-(2-cyanoethyl)-6,7,12,13-tetrahydro-13-methyl-5-oxo-5H-indolo(2,3-a)pyrrolo(3,4-c)-carbazole], an inhibitor of conventional PKCs (␣ and ␤1) reversed axon growth inhibition caused Figure 1 .PKC is required for axon growth inhibition by NG2. A, The effect of PKC inhibitors on axon growth inhibition by various substrates. Dissociated cerebellar granule neurons were grown on the indicated substrates overnight, and the longest neurite of each cell was measured. The histogram plots the mean neurite lengths Ϯ SEM [ϳ111-304 neurons were counted in each condition; n ϭ 4 for the laminin (LM), NG2 CSPG (NG2), and myelin extract (MYE) experiments; n ϭ 3 in chick brain CSPG mixture (CSPG), neurocan (NCN), and aggrecan (AGN) experiments; n ϭ 2 in the ChABC-treated NG2 experiment (NG2ϩChABC); *p Ͻ 0.001, Dunn's post test). B, The inhibitory effect of NG2 on axon growth of adult DRG neurons. Dissociated DRG neurons from adult mice were grown either on control substrates or on NG2-coated substrates in the absence or presence of a cell-permeable peptide inhibitor of PKC (ZIP peptide, 2 M). Left, Typical cell fields. Scale bar, 50 m. The histogram plots the mean neurite lengths Ϯ SEM. Control denotes coverslips coated with laminin. NG2 denotes substrates coated first with 2 g/ml laminin and subsequently with 10 g/ml NG2 (Ͼ36 cells were counted and scored in each condition; *p Ͻ 0.001, Dunn's post hoc test). NS, Not significant. PKC is required for axon growth inhibition. A, RNAi-mediated suppression of endogenous PKC. Rat CGNs were transfected with the indicated amounts of either scrambled or PKC-targeting siRNA. Cell lysates were analyzed by SDS-PAGE and immunoblotting with anti-PKC antibody. The histogram shows densitometric quantitation of the PKC knockdown. A, HT22 cells were transfected with HA-PKC and the indication siRNAs. The levels of HA-PKC in lysates were detected by immunoblotting with anti-HA antibody. B, PKC phosphorylated at T410 (p-PKC) was detected by immunoblotting with specific anti-phospho-PKC antibody. Bath application of soluble NG2 (top) or growth on NG2 coated substrates (bottom) induced the phosphorylation of PKC in CGNs. The histogram shows the fold increase in phospho-PKC Ϯ SEM relative to control cells after normalization to total PKC (n ϭ 3-6; *p Ͻ 0.05, Student's t test). C, PKC phosphorylated at Thr410 in HT22 cells was detected by immunoblotting. Bath application of soluble NG2 (10 g/ml) induced the phosphorylation of PKC in HT22 cells. The histogram shows the mean increase in phospho-PKC Ϯ SEM [n ϭ 3; normalized to control; *not significant (NS); **p Ͻ 0.05, Students' t test]. D, Rat CGNs were transfected with FLAG-PKC, and soluble NG2 (10 g/ml) was bath applied for the indicated times. PKC kinase activity was measured as described in Materials and Methods (n ϭ 3; *p Ͻ 0.01; **p Ͻ 0.05, Students' t test). E, The effect of PKC siRNA on axon growth inhibition. Thirty picomoles of scrambled control or PKC-targeted siRNA along with 1.0 g of dTomato plasmid (pCAGJC-dTomato) were transfected into CGNs. The histogram shows mean neurite lengths Ϯ SEM (n ϭ 1 in scrambled siRNA experiment; n ϭ 3 in control and PKC siRNA experiments; *p Ͻ 0.001, Dunn's post test). F, The effect of phosphomimetic PKC on axon growth. One microgram of indicated PKC expression plasmids along with 1 g of dTomato plasmid were transfected into CGNs. The histogram shows average neurite lengths Ϯ SEM (n ϭ 3; *p Ͻ 0.001, Dunn's post test). G, The effect of kinase-dead (KD) PKC in axon growth inhibition. Approximately 1-2 g of indicated PKC expression plasmids along with 1 g of dTomato plasmid was transfected into CGNs. For the histogram, n ϭ 3. *p Ͻ 0.005 (Dunn's post test). Scale bars: 50 m.
by myelin, mixed chick brain CSPGs, pure neurocan, and aggrecan, but did not reverse inhibition induced by either the ECD of the NG2 proteoglycan (Ughrin et al., 2003) or the ECD after treatment with chondroitinase ABC to remove any covalently attached glycosaminoglycan (GAG) chains. Neither the chick brain CSPG mixture nor myelin membrane preparation contained detectable NG2 (S. Lee and J. Levine, unpublished observation) . A broad range inhibitor of PKC (calphostin C) partially restored neurite growth on NG2-coated surfaces (data not shown), suggesting that additional isoforms of PKC may be involved in growth inhibition. We therefore grew neurons in the presence of a cell-permeable pseudosubstrate peptide inhibitor of atypical PKC (referred to herein as ZIP peptide). Addition of the ZIP peptide (2 M) reversed the growth inhibitory activity of both NG2-coated and myelin-coated substrates but had no effect on inhibition induced by either mixed chick brain CSPGs or the purified CSPGs (Fig. 1A) . NG2 also inhibits the growth of DRG neurons (Dou and , and the ZIP peptide restored normal neurite length to adult mouse DRGs grown on NG2-coated surfaces (Fig. 1B) . These data suggest a role for PKC in NG2 and myelin-induced growth inhibition. Because myelin membranes contain multiple inhibitors of neurite outgrowth that can activate different intracellular signaling pathways (Schwab et al., 2005) , we used purified recombinant NG2 ECD in the following studies to analyze the specific role of PKC in the regulation of axon growth.
NG2 activates PKC
To explore the role of PKC, we used siRNA to knock-down PKC expression. As shown in Figure 2A , transfection of CGNs with a siRNA pool directed against PKC was effective in reducing PKC levels. Western blots of bulk-transfected cultures likely underestimate the extent of knock-down since the transfection efficiency of CGNs was ϳ30 -40%. PKC-targeted siRNA also reduced effectively the expression of HA-tagged PKC in transfected HT22 cells, a neural cell line (Fig. 2AЈ) . Transfection of CGNs with PKC siRNA but not control scrambled siRNA restored normal neurite growth on NG2-coated surfaces (Fig. 2E ). This requirement for PKC suggests that the enzyme may be activated by NG2 treatment. PKC activation is a two-step process: phosphorylation of T410 releases the kinase from inhibition allowing autophosphorylation of T560 and full activation (Chou et al., 1998; Standaert et al., 2001 ). We measured the phosphorylation of T410 on immunoblots as an indication of the activation of PKC by NG2. Short-term treatment of CGNs with soluble NG2 led to a modest but significant increase in the phosphorylation of T410. This increase was sustained for as long as 24 h when the cells were grown on NG2-coated surfaces (Fig. 2B) . To measure kinase activity directly, we developed an in vitro kinase activity assay using HT22 cells. Similar to CGNs, HT22 cells respond to short-term treatment with soluble NG2 with an increase in T410 phosphorylation (Fig. 2C) . To avoid assaying the activation of conventional or novel PKCs, we designed an assay to measure specifically PKC activity. Cells were transfected with FLAG-tagged PKC, the kinase was then immunoprecipitated with anti-Flag antibodies, and the immunoprecipitates were incubated with 32 P␥-ATP and peptide substrates and inhibitors specific for either conventional, novel, or atypical PKCs. PKC activity is defined as cpms incorporated into the atypical PKC peptide substrate minus cpms incorporated in the presence of ZIP peptide. In this assay, Gö6976 had no effect on specific PKC activity. Short-term treatment of transfected rat CGNs resulted in an increase in PKC activity (Fig. 1D) . To determine whether the phosphorylation and activation of PKC is sufficient to inhibit axon growth from Figure 3 . Enrichment of PKC in membrane fractions induced by NG2 treatment. A, CGNs were grown overnight on control or NG2-coated dishes. After cell lysis, cytoplasmic and membrane fractions were prepared as described in Materials and Methods, and PKC in each fraction was detected by SDS-PAGE followed by immunoblotting with anti-PKC. Treatment of the cells with PMA had no effect on the compartmentalization of PKC. The histogram shows fold changes in PKC levels in cytoplasmic and membrane fractions after NG2 treatment (n ϭ 3). Addition of ZIP peptide prevented the increase in membrane-associated PKC (n ϭ 2). *p Ͻ 0.05, Student's t test. B, NG2 treatment translocates PKC to the membrane. Rat CGNs were plated on the surfaces coated either with laminin only or with laminin plus NG2, grown for 24 h, and fixed and stained with anti-PKC antibody. The top panel shows strong PKC immunoreactivity associated with the membrane of cells grown on the NG2-coated substrate. Shown below are line scans of fluorescence intensity through the cell bodies (n ϭ 6). C, Rat CGNs transfected with GFP-tagged PKC were grown on either control or NG2-coated substrates for 24 h. The distribution of fluorescence was analyzed using confocal microscopy. Fluorescence was condensed at the membrane of cells grown on NG2. Scale bars: 10 m.
rat CGNs, we created two phosphomimetic forms of PKC by converting T410 and T560 to glutamic acid (Chou et al., 1998; Standaert et al., 2001 ). Expression of either T410E or both T410E and T560E reduced significantly axon lengths on laminin-coated substrates (Fig. 2F ). CGNs transfected with a kinase-dead mutant of PKC (Romanelli et al., 1999) were not growth-inhibited on NG2 substrates, whereas transfection with wild-type PKC had no effect on NG2-induced growth inhibition (Fig. 2G) . When activated, PKC isoforms are translocated from a cytoplasmic compartment to the plasma membrane (Mosthaf et al., 1996; Standaert et al., 1999; Kazi and Soh, 2007) . We therefore measured changes in the amount of PKC associated with cytoplasmic or membrane fractions of rat CGNs grown on either control laminin alone or NG2 plus laminincoated surfaces for 24 h. As shown in Figure 3A , there was a significant increase in the amount of PKC associated with the plasma membrane and a decrease in the cytoplasmic pool of PKC after growth on NG2. Short-term treatment of the cultures with PMA had no effect on the compartmentalization of PKC, whereas addition of the ZIP peptide (2 M) 3 h before lysis prevented this increase in membrane association. Last, we grew CGNs on either laminincoated surfaces or surfaces coated with laminin and NG2 for 24 h and immunofluorescently stained the cells with antibodies against PKC. The distribution of PKC was analyzed using confocal microscopy. As shown in Figure 3B , there was an increase in the association of endogenous PKC with the plasma membrane. In cells transfected to express EGFP-PKC, there was also an increase in membrane-associated fluorescence after plating on NG2-coated surfaces (Fig. 3C) . Thus, by three different criteria, treatment of rat CGNs with soluble or substrate-bound NG2 activates PKC, and this activation is both necessary and sufficient to inhibit axon elongation.
NG2 activates Cdc42 and the Par complex
PKC is a component of the Par complex that is usually associated with the development of neuronal polarity rather than the regulation of axon elongation. During axonogenesis, Cdc42 binds to and activates Par6. Par6 normally inhibits PKC, but after Cdc42 binding, PKC becomes disinhibited (Lin et al., 2000; Etienne-Manneville and Hall, 2001; Yamanaka et al., 2001; Macara, 2004; Hurd and Margolis, 2005; Nishimura et al., 2005) . The complex of PKC, Par6, and Par3 is subsequently transported to the ends of differentiating axons where it induces growth cone formation and axon elongation (Shi et al., 2003; Nishimura et al., 2004) . Since the functions of the Par complex can vary according to cellular context and protein-protein interactions Ozdamar et al., 2005; Nakayama et al., 2008; Zhang and Macara, 2008; Yi et al., 2010) , we performed a series of experiments to determine the roles of Cdc42 and Par6 in the activation of PKC by NG2 and to ask whether, once activated by NG2, there are changes in Par complex stoichiometry, localization, and/or function.
We measured changes in the association of Par6 and Cdc42 as an assay for Cdc42 activation by exogenous NG2. To confirm that the increased binding of Cdc42 to Par6 is a measure of Cdc42 activation, HT22 cells were transfected with dTomato-tagged Cdc42 and myc-tagged Par6, and the amount of Cdc42 bound to Par6 was measured from immunoblots after immunoprecipitation of Par6. As shown in Figure 4A , incubation of transfected cell lysates with GTP␥S but not GDP increased the binding of Cdc42 to Par6. Treatment of transfected HT22 cells with soluble NG2 for 5 and 20 min increased the binding of Cdc42 to Par6 (Fig. 4A) . To determine whether the activation of Cdc42 is required for the NG2-induced increases in PKC phosphorylation, we transfected HT22 cells with either wild-type or DN Cdc42 (T17N) and measured the phosphorylation of T410 in FLAG-tagged PKC. Expression of DN-Cdc42 prevented NG2-induced increases in T410 phosphorylation (Fig. 4B) . Wild-type Cdc42 bound strongly to Par6, whereas the dominant-negative form did not (Fig.  5A) . We next examined the effects of manipulating Cdc42 activity on axon growth from CGNs. Transfection of CGNs with DN-Cdc42 reversed growth inhibition on NG2-coated surfaces (Fig. 4C) , whereas transfection with a CA mutant of Cdc42 (Q61L) was sufficient to inhibit neurite outgrowth on control laminin-only substrates (Fig. 4D) . Thus, NG2 treatment activates Cdc42, and this activation is necessary for both the activation of PKC and for NG2-induced axon growth inhibition. CA-Cdc42 is sufficient to inhibit neurite outgrowth on control laminincoated substrates.
To determine whether the increased association of Par6 and active Cdc42 is necessary for axon growth inhibition, we transfected cells with two mutant forms of Par6 lacking the semi-CRIB domain that binds to activated Cdc42 (Lin et al., 2000; Nishimura et al., 2005) . Wild-type Par6 forms complexes with Cdc42 in vivo, but these mutants do not. All forms of Par6, however, are bound to PKC (Fig. 5A) . When transfected into CGNs, these mutant forms of Par6 significantly reversed NG2-induced growth inhibition (Fig.  5B) . Together, these data show that NG2 treatment activates Cdc42 and increases its association with Par6, and both the activation and increased association are necessary for axon growth inhibition.
We next asked whether NG2 treatment changes the association of PKC and Par6. As shown in Figure 6A . After 16 -24 h, cell lysates were immunoprecipitated by anti-Myc antibody and blotted with antibodies against Myc, FLAG, and PKC. Semi-CRIB domain mutants failed to bind to Cdc42, whereas they are still able to associate with PKC. B, A Par6-Cdc42 interaction is necessary for growth inhibition. CGNs were transfected with Par6 mutants (⌬135P and ⌬CRIB), and neurite lengths were measured as above (n ϭ 3; *p Ͻ 0.001, Dunn's post test). Scale bar, 50 m.
1-129, PKC NT) that competes for Par6 binding and grew the cells on control or NG2-coated surfaces. The expression of PKC NT reduces the association of PKC and Par6 in CGNS (Fig. 6B ) and reverses NG2-induced axon growth inhibition (Fig. 6C) . Expression of WT PKC had no effect on NG2-induced inhibition. Together, these results show NG2 treatment of CGNs activates the Par complex and this activation is necessary for growth inhibition.
Atypical PKC and the Par complex regulate the development of polarity in embryonic hippocampal neurons (Shi et al., 2003; Nishimura et al., 2005) . Inhibition of PKC prevents polarization (Shi et al., 2003) , and activation of the kinase promotes polarization and axonogenesis (Zhang et al., 2007) . Enhancing the activity of PKC can lead to aberrant polarization and the formation of multiple axons per cell (Zhang et al., 2007) . To confirm a functional activation of PKC by NG2 in a system other than postnatal CGNs, we asked whether substrate-bound NG2 could affect the polarization of embryonic day 18 rat hippocampal neurons. We grew the cells on surfaces coated with either PLL or PLL and NG2, and measured the number of cells with and without axons. As shown in Figure 7A , hippocampal neurons grown on NG2-coated surfaces rapidly extended Tau-positive axonal processes, such that after 48 h in culture, a higher percentage of the cells had one or more axons. This percentage was reduced to control levels when the cells were grown on NG2 in the presence of 2 M ZIP peptide. Typical cells (48 h in culture) stained with phalloidin and anti-Tau antibodies are also shown in Figure 7A . The control cell has one long axonal process and several short processes emanating from the cell body and corresponds to stage 3/4 of polarization (Dotti et al., 1988) . The cell grown on NG2 has four long Tau-positive axonal processes. Thus, NG2 treatment perturbs the development of polarity in embryonic hippocampal neurons, and this perturbation is dependent on PKC activity.
NG2, as well as other CSPGs, form barriers that growing and sprouting axons avoid in vitro and in vivo (Snow et al., 1990; Dou and Levine, 1994; Powell et al., 1997; Asher et al., 2000; Tan et al., 2006) . We reasoned that if the inhibitory effect of NG2 on growing axons is via an activation of PKC, manipulating PKC should also alter axonal behavior in barrier assays such as the widely used stripe assay (Vielmetter et al., 1990) . As shown in Figure 7B , axons of embryonic chicken retinal ganglion cells avoid NG2 to an extent similar to the avoidance of ephrin-A5 in the stripe assay. This avoidance of NG2 stripes was reduced by addition of ZIP peptide, whereas the avoidance of ephrin-A stripe was not affected. Pretreating the ZIP peptide with proteinase K to cleave and inactivate it restored avoidance of NG2 stripes. Heatinactivated proteinase K had no effect on axon growth in this assay. Since the retinal ganglion cells shown here have already polarized and are actively extending axons, these data demonstrate that growth cone contact with NG2 causes the repulsion of actively growing axons, and that this repulsion requires the activation of PKC.
NG2 treatment activates Rac1 GTPase
How does the activation of PKC and the Par complex lead to reduced axon extension? Most of the effects of the Par complex on the cytoskeleton and cell motility are mediated through Par3 which plays a central role in regulating Rac1 activity (Chen and Macara, 2005; Nishimura et al., 2005; Nakayama et al., 2008) . Since Par3 may function independently from any associations with other Par complex proteins (Chen and Macara, 2005) , we first examined the associations of PKC with Par3. Treatment of transfected HT22 cells or CGNs with NG2 reduced the amount of Par3 coimmunoprecipitated with PKC (Fig. 8A) . There was also less PKC present in anti-Par3 immunoprecipitates. This NG2-dependent reduction in the interactions of Par3 and PKC was prevented by either transfecting cells with a kinase-dead mutant of PKC or treating the cells with ZIP peptide (Fig. 8B) A, NG2 promotes axon formation in hippocampal neurons. E18 hippocampal neurons were grown on PLL-or NG2-coated surfaces for 24 -48 h and cell polarization analyzed as described in Materials and Methods. The bar graph shows the percentage of neurons with the indicated number of axons (n ϭ 3; Ͼ136 cells were counted and scored in each condition). The panels below show a typical stage 3/4 cell on control substrate and a multiaxonal cell grown on NG2 immunofluorescently stained with anti-Tau antibodies (red) and Alexa Fluor 488 phalloidin (green). Scale bar, 20 m. B, The avoidance of NG2 in the stripe assay requires PKC activity. E7 chick retina was grown on striped surfaces coated with NG2 (purple), and living cultures were treated as indicated. The histogram below plots the percentage of neurites growing on the stripes. PK, Proteinase K. *p Ͻ 0.001. n ϭ 4 -6 for each condition. dependent activation of PKC or in regulating its protein-protein interactions.
The binding of Par3 and PKC is regulated by multiple phosphorylations of Par3. Phosphorylation of T833 by ROCK or S827 by atypical PKC reduces Par3-PKC binding (Nagai-Tamai et al., 2002; Nakayama et al., 2008) . Because inhibiting ROCK had no effect on the reduced PKC-Par3 binding caused by NG2, we mutated S824 of human Par3 (the equivalent of rat Par3 S827) to alanine and tested the effects of this mutation on NG2-induced growth inhibition. Expression of phosphomutant Par3 was able to reverse NG2-mediated neurite growth inhibition (Fig. 8C) , suggesting that PKCmediated phosphorylation of Par3 is necessary for growth inhibition.
We next asked whether NG2 treatment activates Rac1. To measure the activation of Rac1, we designed a second in vivo assay: we transfected cells with myc-tagged pak1 and dTomato-tagged Rac1 and measured the binding of Rac1 to pak1 by immunoprecipitation and immunoblotting. As shown in Figure 9A , short-term treatment with NG2 increased the binding of Rac1 to pak1, and this was prevented by the ZIP peptide or expressing phosphomutant Par3 (S824A). To determine the role of Rac1 in neurite growth inhibition, we transfected cells with DN (T17N) or CA-Rac1(G12V). Expression of DN-Rac1 prevented NG2-induced neurite growth inhibition (Fig. 9B) , and expression of a CA-Rac1 mutant was sufficient to inhibit neurite growth on control laminin-coated surfaces (Fig. 9C) .
Last, we asked whether NG2 treatment altered the intracellular distribution of Par3. In CGNs grown on control surfaces, Par3 was found in the cell body, axon shaft, and growth cone (Fig. 10) . After growth on NG2-coated surfaces for 24 h, the relative amount of Par3 immunoreactivity in the cell body increased, whereas immunoreactivity in axon shafts was reduced. Together, these data suggest a model in which NG2 binding to an unidentified receptor on CGNs (Dou and leads to the activation of Cdc42. This increases the binding of Par6 to PKC and activates (or disinhibits) the enzyme. PKC phosphorylates Par3 at S827, releasing it from PKC. Par3 then accumulates in cell bodies leading to the spatially inappropriate activation of Rac1 GTPase and reduced neurite growth.
Discussion
Here, we have shown that atypical PKC function is required for axon growth inhibition caused by exposing both neonatal and adult neurons to the extracellular domain of the NG2 CSPG. PKC activity, along with that of other isoforms of PKC, is also involved in growth inhibition by myelin membranes (Hasegawa et al., 2004 , Sivasankaran et al., 2004 . Although PKC can have kinase activityindependent functions (Kim et al., 2009 ), short-and long-term exposure to NG2 activates PKC, and this activation is both necessary and sufficient for axon growth inhibition. This activation of PKC leads to changes in the function and location of Par complex proteins and the activation of Rac1. Thus, in addition to regulating axon specification, the Par complex regulates axon extension, and this regulation can be negatively modified by extracellular signals. These results define a new role for the Par complex and suggest that the Par complex and PKC may be important targets for interventions designed to encourage axon regeneration after injury.
In developing hippocampal neurons, a consequence of PKC activation by exogenous NG2 is aberrant polarization and axonogenesis, including the development of multiple axons per cell. This ability of NG2 to promote axonogenesis in embryonic neurons may be why others (Yang et al., 2006b; Busch et al., 2010) concluded that NG2 can be a favorable substrate for growing axons. In neonatal and adult neurons, however, NG2-induced activation of PKC reduces axon extension. This suggests that the effects of activation of PKC vary according to cell type, developmental stage, and in vitro context and likely reflects different Figure 8 . The modification of a PKC-Par3 complex by NG2. A, NG2 treatment dissociates a PKC-Par3 complex. NG2 (10 g/ml) was bath applied for 30 min to HT22 cells and CGNs transfected with FLAG-PKC and myc-Par3. The binding of these proteins was detected by immunoprecipitation followed by immunoblotting with epitope-specific antibodies. The histogram to the right shows the mean Ϯ SEM decrease in Par3-PKC binding in HT22 cells (n ϭ 3, normalized to control; *p Ͻ 0.05, Student's t test). B, PKC activity is required for the dissociation of the PKC-Par3 complex. NG2 (10 g/ml) was applied for 30 min to HT22 cells transfected with Par3 and either WT or kinase-dead (KD) forms of FLAG-PKC in the absence or presence of ZIP peptide (2 M) or Y27632 (10 M). The PKC-Par3 complex was detected by immunoprecipitation with anti-FLAG antibody, followed by immunoblotting with specific anti-myc or FLAG antibody. Quantitation of the results is shown to the right (n ϭ 3, normalized to control treatment; *p Ͻ 0.05, Student's t test). C, Expression of a phosphorylation-deficient mutant Par3 (S824A) prevents axon growth inhibition. CGNs were transfected with either WT or phosphorylation-deficient Par3 and grown on control or NG2-coated substrates. The histogram shows the quantitation of neurite lengths (mean Ϯ SEM; n ϭ 3; *p Ͻ 0.001; Dunn's post test). NS, Not significant. Scale bar, 50 m.
functions for the Par complex at different stages of neuronal differentiation. In addition to its effects on neonatal CGNs and adult DRGs, NG2 repels chick retinal ganglion cell growth cones in the stripe assay, also in a PKC-dependent manner. Growing neurons on uniformly coated substrates measures the ability of substrate molecules to affect axon extension, whereas the stripe assay measures decision making by growth cones. This assay may better reflect axonal behaviorafterinjuryinvivo,whereagrowthcone confronts a myriad of growth-promoting and growth-inhibiting molecules.
During the intrinsic polarization of hippocampal neurons, there is a requirement for the activation of Cdc42, which subsequently binds to Par6, resulting in the disinhibition of PKC (Lin et al., 2000; Etienne-Manneville and Hall, 2001; Yamanaka et al., 2001; Macara, 2004; Hurd and Margolis, 2005) . The inhibition of axon growth by exogenous NG2 also required Cdc42. Because of the low level of Cdc42 expression in CGNs and the liability of bound GTP in cell lysates, we developed a novel in vivo Par6 binding assay to demonstrate that Cdc42 is activated after short-term treatment with NG2. Cdc42 activation is required for NG2 effects on growing axons since the expression of DN-Cdc42 reversed axon growth inhibition and prevented the activation of PKC. Moreover, expression of CA-Cdc42 inhibited neurite growth of CGNs on laminin surfaces as it also does for embryonic hippocampal neurons (Nishimura et al., 2005) . The expression of DN-Cdc42 promotes neurite growth on collapsin-1 (semaphorin 3D)-coated surfaces (Jin and Strittmatter, 1997; Kuhn et al., 1999) , suggesting that other growth inhibitory molecules may also activate PKC and the Par complex.
NG2 treatment increased the binding of Par6 to PKC, and this binding too was required for growth inhibition. Since wild-type and CA-Cdc42 but not DNCdc42 bind strongly to Par6, the enhanced binding of Par6 to PKC caused by NG2 treatment may increase the sensitivity of the kinase to activation by Cdc42. Indeed, overexpression of Par6 in COS cells is sufficient to increase PKC activity (Qiu et al., 2000) . The physiological modulation of Par6 -PKC binding shown here may be a novel mechanism for the regulation of the Par complex function by extracellular molecules.
We also showed that NG2 treatment activates Rac1 in CGNs and that this activation is also necessary and sufficient to inhibit neurite extension. Both the activation of Rac1 and the inhibition of growth Figure 9 . NG2 activates Rac1 to inhibit axon growth. A, NG2 was bath applied for 5 min to HT22 cells transfected with epitope-tagged PAK1 and Rac1 in the absence or presence of ZIP peptide (2 M) for 5 min. Rac1 binding to transfected PAK1was measured by immunoprecipitation with anti-myc antibody followed by immunoblotting with anti-dsRed. The histogram to the right shows that NG2 increased Rac1 binding to PAK1, and this was prevented either by adding ZIP peptide or expressing the phosphorylation-deficient mutant form of Par3 (n ϭ 3, normalized to control; *p Ͻ 0.05, Student's t test). B, Rac1 activation is required for axon growth inhibition. CGNs were transfected with either WT or DN-Rac1 (T17N) and grown on control or NG2-coated substrates. DN-rac1-expressing CGNs were able to extend long axons on NG2 substrates, similar to the cells grown on control substrates. The histogram shows mean neurite lengths Ϯ SEM (n ϭ 3; *p Ͻ 0.001, Dunn's post test). C, Constitutively active Rac1 is sufficient to inhibit axon growth from CGNs. WT or CA-Rac1 (G12V) was transfected into CGNs. CA-Rac1-expressing CGNs extended only short stubby axons on control substrates. The histogram shows mean neurite lengths Ϯ SEM (n ϭ 3; *p Ͻ 0.001; Dunn's post test). Scale bars: 50 m. require active PKC and a phosphorylatable serine residue at position 824 in Par3. Par3 binds TIAM (T-lymphoma invasion and metastasis-inducing protein) and STEF (Sif-and Tiam1-like exchange factor), guanine exchange factors that directly activate Rac1, and this binding can either positively or negatively regulate Rac1 activity. For example, in epithelial cells, Par3 may sequester TIAM away from Rac1, thereby reducing activity (Chen and Macara, 2005) . In polarizing hippocampal neurons, however, STEF is bound to the Par complex via Par3 and activates Rac1 in a Cdc42-dependent manner (Nishimura et al., 2005) . During polarization and axon specification, Par3 along with PKC, STEF, and Rap1B becomes localized at the tip of the neurite that will develop into the axon. Disrupting this distribution causes defects in polarization (Schwamborn and Puschel, 2004; Nishimura et al., 2005; Schwamborn et al., 2007) . One consequence of NG2 treatment of CGNs is the accumulation of Par3 in neuronal cell bodies, possibly due to interference with Par3-kif3A interactions (Nishimura et al., 2004) . We speculate that the accumulation of Par3 in cell bodies leads to a spatially inappropriate activation of Rac1 and compromised axon extension. Balanced Rac1 and RhoA activity is required for neurite extension (Woo and Gomez, 2006) , and disturbances of this balance may explain why CA-Rac1 inhibits neurite growth from CGNs as reported here and rat cortical neurons (Kubo et al., 2002) but promotes growth from embryonic hippocampal neurons (Schwamborn et al., 2007) and postnatal neuronal progenitor cells (Khodosevich and Monyer, 2010) . Unbalanced and spatially inappropriate activation of Rac1 activity in damaged axons after SCI may be one reason why transected axons fail to reform growth cones and initiate regrowth (Bradke et al., 2012) .
Not all the effects of NG2 on axon growth, however, may be due to inappropriate Rac1 activation. Whereas the expression of CA-Rac1 leads to short neurites with lamellipodial-like extensions, the axons of cells grown on NG2 while short have collapsed growth cones but no lamellipodia (Dou and Ughrin et al., 2003) . CSPGs and myelin-associated axon growth inhibitors are thought to activate Rho, although recently the significance of this activation for growth inhibition by myelin has been questioned (Park et al., 2010) . Although NG2 treatment increases Rho-GTP in CGNs (W. Zhang and J. Levine, unpublished observation) , treatment of cells with the ROCK inhibitor Y27632 did not prevent the NG2-induced reduction in Par3-PKC binding. PKC phosphorylates rodent Par3 at S827 (Lin et al., 2000; Nagai-Tamai et al., 2002) , and ROCK phosphorylates Par3 at T833 (Nakayama et al., 2008) . Since the expression of a phosphomutant Par3 (S824A) restored normal neurite lengths on NG2 surfaces and prevented the activation of Rac1, we conclude that Rhoactivation is not necessary for the NG2-induced, Par3-dependent activation of Rac1. Rather, the activation of Rac1 is dependent upon the activation of PKC. It is possible, however, that growth inhibitory molecules such as NG2 activate Rho downstream of PKC, and Rho together with Rac1 compromise the function of actin and microtubule-based cytoskeletal motors.
NG2 is one of several CSPGs whose expression is rapidly increased at sites of spinal cord injury (Tang et al., 2003) . NG2 has a unique protein structure (Staub et al., 2002) and, unlike other injury-associated CSPGs such as neurocan, aggrecan, and versican, contains relatively low amounts of covalently bound chondroitin sulfate glycosaminoglycan chains. Thus, it is not surprising that NG2 activates intracellular signaling pathways differently than those CSPGs such as neurocan that bind to PTP via their GAG chains (Shen et al., 2009 ). In addition to CSPGs, numerous repulsive axon guidance molecules and myelin-associated inhibitors accumulate at sites of CNS injury (Yiu and He, 2006). While it seems unlikely that there is one common pathway by which these diverse molecules inhibit axon regeneration, several lines of evidence, in addition to the data presented here, point to the Par complex as a potential new and novel intracellular mediator of growth inhibition and repulsive axon guidance. Wnt5a is increased at sites of spinal cord injury and prevents the regeneration of descending corticospinal tract axons in rodents Miyashita et al., 2009 ). Similar to NG2, Wnt5a activates PKC (Wolf et al., 2008) , promotes the polarization of hippocampal neurons (Zhang et al., 2007) , and inhibits the growth of CGNs in vitro (Miyashita et al., 2009 ). Genetic knock-out studies suggest that the phosphatase and tensin homolog (PTEN) plays a major role in preventing nerve regeneration after optic nerve crush (Park et al., 2008) and spinal cord injury . The exact mechanisms of PTEN-mediated inhibition of regeneration are unknown, but high PTEN activity perturbs Par complex function. In developing hippocampal neurons, overexpression of PTEN reduces PIP3 levels, resulting in a failure to properly target Par3 to axon tips and reduced neuronal polarization (Shi et al., 2003; Ménager et al., 2004) . In this regard, it is interesting that knocking down PTEN partially rescues neurons from MAG-induced growth inhibition (Perdigoto et al., 2011) .
In summary, we have identified a new role for Par complex proteins in the negative regulation of axonal growth and showed that a major CSPG that accumulates at sites of brain and spinal cord injury Jones et al., 2002) activates PKC and the Par complex. Inhibition of axon growth by myelin also depends partially on the activity of PKC. These findings emphasize the functional diversity of PKC and the Par complex proteins in axonal growth regulation. Further genetic and functional studies will be necessary to fully elucidate the functions of the Par complex in axon regeneration and repair.
